

INVESTOR WEBINAR PRESENTATION

Friday 26 March 2021, 12.30pm (AEDT) – ShareCafé Small Cap “Hidden Gems” series

Adelaide, Australia, 25 March 2021: LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce that the Company’s CEO and Managing Director, Brent Barnes, will be presenting at the ShareCafé Small Cap “Hidden Gems” webinar at 12.30pm on Friday 26 March 2021 (AEDT).

The webinar will be held online as part of the regular ShareCafé Hidden Gems series focussed on micro and small cap ASX-listed companies. Mr Barnes will provide a 10 minute presentation on LBT followed by a 5 minute question and answer session.

To register to attend this free investor event, please use the following link:

https://us02web.zoom.us/webinar/register/5416151767246/WN_6rhA6DEiSXyTupSAOnsQ7Q

The Company’s presentation for the conference is attached.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company’s second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT’s 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT’s intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

| LBT Innovations | Investor Enquiries |
|---|---|
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com | David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com |



LBT INNOVATIONS

Using AI to disrupt the \$5.3bn clinical microbiology market

Early commercialisation - Global launch

ShareCafe
26 March 2021

Brent Barnes
CEO & Managing Director

ASX code: LBT

lbtinnovations.com

Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.

Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

Clinical microbiology: US\$3.9bn global market*

Exciting market opportunity - growing at 6.5% per annum



Rising incidence of infectious diseases

>150 million UTI infections per yr



Outbreak of epidemics - Huge demand on clinical resources driven by COVID-19



Technology advancements - New products needed to meet growing testing demand



Increasing investment from public and private sector



* Market Research Report, marketsandmarkets.com (Oct 2020): Clinical Microbiology Market by Application (Food, Pharma, Manufacturing, Chemical, Environment), Disease (Respiratory, Std, Uti), Product (Instrument, Analyzer, Reagent), End User (Hospital, Diagnostic Lab, Academia) - Global Forecast to 2025

Challenges facing microbiology laboratories

Culture plates reading remains a highly manual process



High Volume - >6.5 million culture plates read per day and growing



High Cost - Requires highly trained scientists to interpret results



Limited Resources - Declining workforce with high vacancy rates (6% in US)



Patients rely on rapid and accurate test results to inform treatment

Cutting edge AI technology for microbiology

APAS® Independence - **First** and **only** automated culture plate reader

 **Innovative** platform technology
One product – multiple laboratory tests

 **Patent** protected
4 issued patent families

 **Clinically proven**
10,000-patient clinical trial

 Global regulatory clearances
FDA, CE Mark, TGA

 Product **launched**
Global sales - US, Australia, Germany


 Channel partners
EU Beckman Coulter; US Distribution Pending



APAS INDEPENDENCE

Global product launch

Sales achieved in launch markets. Establishing partnerships to scale



2020 formed key partnerships to scale

COVID-19 highlighted the need for automation in microbiology



Global healthcare distributor

Top 4 global distributor with US\$3.6bn of sales and 12,000 staff worldwide



EU sales and marketing agreement

Expanded sales presence Germany, UK and France



Hybrid distribution model

Joint customer partnerships to win



Expanded European sales presence

Germany, UK and France



Field service and support partner



oneservice™ engineer at The Doctors Laboratory, London



Technology adoption

Targeted sales approach focussed on early adopters



Hennepin Health



Labor Dr Wisplinghoff

Innovators

Key Opinion Leaders

St Vincent's Melbourne (AU),
Hennepin Health (US), Labor
Dr Wisplinghoff (EU)



Early Adopters

Technology Leaders

First commercial sales –
Limbach Group (EU)



Early Majority



“We are very pleased to incorporate the APAS® Independence into our routine clinical workflow, where the instrument will be used daily to automate the reading of our MRSA cultures.”
– Prof. Hilmar Wisplinghoff

Exciting market opportunity

Dual strategy of **direct** to market sales and **distributor** appointments

Number of labs globally

Small Labs

<400 plates per day

15,000

Medium Labs

400 - 1000 plates per day

12,000

Large Labs

>1000 plates per day

1,000

Total Market Opportunity 13,000

Market Opportunity (AU, US, EU)



Addressable Market: >2,000 Labs

Market penetration: 20-30%

Instrument sales: 400-600

5yr opportunity: ~US\$450k/APAS

Sales estimate: US\$140m-\$270m*

50:50 Joint Venture
Profits shared equally



**CLEVER CULTURE
SYSTEMS**

* Sales estimate includes expected distributor margin

Corporate overview


Strong balance sheet for growth - funding runway extends into 2022

Key Statistics (Closing price on 16 March 2021)

| | |
|-------------------------|-------------------|
| Share Price | \$0.098 per share |
| 24 -month range | \$0.080 - \$0.230 |
| Number of shares | 289.1 million |
| Options Issued | 11.9 million |
| Market Cap | ~\$28.3million |

Financials (AUD)

| | |
|---------------------------|---|
| Cash | \$12.0 million (as at 31 Dec 20) + \$0.8 million (R&D Tax Incentive - 26 Feb 21) |
| Cash burn | ~\$1.5m per Qtr (prior to sales revenue inflows and SAFA repayments) |
| SAFA Loan Facility | \$4 million - Low interest rate, 5-year term |
| Key Shareholders | Institutions (5.7%) and Industry (5.7%), Directors + Management (1.8% + Options) |



Investment highlights and outlook

No better time to be in microbiology diagnostics

Technology proven - \$31.5m invested

Invented **first-in-class** technology (patent protected)

Global regulatory clearances - **FDA, CE Mark, TGA**

First sales achieved (**US, Australia, Germany**)

Partnerships to scale (**Beckman Coulter, oneservice™**)

Funded to grow - \$12m Cash + R&DTI \$0.8m received



2021 Commercial outlook

Expanded technology platform

- **USA: MRSA analysis module FDA Clearance**
- **EU and Australia: VRE and Urine analysis modules**

Growing instrument sales

US channel partner appointed



LBT INNOVATIONS

LBT Innovations

Level 8, 44 Waymouth Street

Adelaide SA 5000

+61 (0)8 8227 1555

info@lbtinnovations.com

lbtinnovations.com